Tirzepatide

Tirzepatide is a synthetic 39-amino-acid peptide developed by Eli Lilly. It is a dual agonist of the GIP and GLP-1 receptors, carries a C20 fatty diacid side chain on Lys20 that binds albumin, and ends in a C-terminal amide. It is an FDA-approved active ingredient; the material sold here is a research reagent, not a medicine.

Yes. Tirzepatide is a 39-amino-acid peptide whose sequence is based on GIP (glucose-dependent insulinotropic polypeptide). It includes a few non-standard amino acids, such as α-aminoisobutyric acid (Aib), and a fatty-acid side chain.

Semaglutide is a 31-amino-acid analogue of GLP-1 that activates the GLP-1 receptor only. Tirzepatide is a 39-amino-acid peptide built on the GIP sequence that activates both the GIP and GLP-1 receptors. Both carry a fatty diacid side chain that binds albumin and extends their persistence in research systems: C18 on semaglutide's Lys26, C20 on tirzepatide's Lys20.

Both are synthetic, fatty-acid-modified peptides developed by Eli Lilly. Tirzepatide is a dual agonist of the GIP and GLP-1 receptors and is an FDA-approved active ingredient. Retatrutide (LY3437943) is a triple agonist that also activates the glucagon receptor, and as of October 2026 it remains investigational and is not FDA approved. The material sold here, in either case, is a research reagent.

All three are fatty-acid-modified synthetic peptides studied in incretin research, and they differ mainly in receptor targets. Semaglutide (Novo Nordisk) activates the GLP-1 receptor only. Tirzepatide (Eli Lilly) activates the GIP and GLP-1 receptors. Retatrutide (Eli Lilly) activates the GIP, GLP-1 and glucagon receptors. Semaglutide and tirzepatide are FDA-approved active ingredients; retatrutide is investigational and not FDA approved as of October 2026. All three are sold here as research reagents.

Tirzepatide was characterized in cell and rodent studies of GIP and GLP-1 receptor signaling, including how one molecule engages both incretin receptors. Eli Lilly then ran large clinical-trial programs in people with type 2 diabetes and in people with obesity, and it is an FDA-approved active ingredient. Findings in cells or animals do not establish effects in people. The material sold here is a research reagent, not a medicine.

Yes, as the active ingredient of prescription medicines; the FDA first approved tirzepatide in 2022. That FDA approval covers finished medicines made under pharmaceutical manufacturing controls and dispensed by prescription. The tirzepatide sold here is a laboratory research reagent, not a medicine, and is not for human or veterinary use.

Not only. Tirzepatide is a dual agonist: its 39-amino-acid sequence is based on GIP (glucose-dependent insulinotropic polypeptide), and it activates both the GIP receptor and the GLP-1 receptor. It does not target the GLP-2 receptor. It is often grouped with GLP-1 agonists, but it is more precisely described as a GIP/GLP-1 receptor agonist.

For storage, yes. Keep sealed, lyophilized tirzepatide refrigerated at 2–8 °C, or frozen at −20 °C or below for long-term storage, away from light and moisture. Once reconstituted, keep it refrigerated and avoid freeze-thaw cycles. Like any peptide it slowly degrades over time, so check the vial label and the lot's Certificate of Analysis for storage guidance and dates.

These peptides act on different receptors. Tesamorelin is a 44-amino-acid analogue of growth-hormone-releasing hormone (GHRH) that acts on the GHRH receptor. Tirzepatide is a 39-amino-acid, fatty-acid-modified agonist of the GIP and GLP-1 receptors. Both are FDA-approved active ingredients of prescription medicines; the material sold here, in either case, is a research reagent.

No. MOTS-c is a 16-amino-acid mitochondrial-derived peptide and has no sequence relationship to GLP-1. It is studied in connection with the AMPK pathway rather than incretin receptors. Retatrutide, tirzepatide and semaglutide, by contrast, are fatty-acid-modified peptides designed to activate the GLP-1 receptor (and, for the first two, the GIP and, for retatrutide, glucagon receptors).

They are entirely different designs. Adipotide is a peptidomimetic built to bind prohibitin on blood vessels of white adipose tissue and carry a membrane-disrupting D-amino-acid sequence. Retatrutide, like tirzepatide and semaglutide, is a fatty-acid-modified incretin receptor agonist that activates hormone receptors (GIP, GLP-1 and glucagon for retatrutide). Adipotide does not act on these receptors.

Tirzepatide: molecular formula C225H348N48O68; molecular weight 4813.5 g/mol; CAS number 2023788-19-2. Sequence: YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS (X = Aib; Lys20 acylated with a C20 fatty diacid via gamma-Glu-2xAEEA linker; C-terminal amide). Match these identifiers against the Certificate of Analysis for the lot.

Yes. Each lot has its own Certificate of Analysis, linked on this page for the current lot of each size: 5mg (98.85% HPLC purity); 40mg (98.98% HPLC purity); 120mg (98.74% HPLC purity). Past certificates are archived in the COA library; contact us with the lot number on the vial label if a certificate is missing.

98.74% (HPLC, current lot). Purity is measured by high-performance liquid chromatography (HPLC) and reported on the lot's Certificate of Analysis.

Tirzepatide is supplied as lyophilized powder in a sealed vial in 3 sizes: 5mg, 40mg, 120mg. In stock and dispatched in 1–2 business days. Quantity pricing applies automatically at 5+ and 10+ vials of the same size.

Store sealed at −20 °C, dry and protected from light.